Officially registered in June 2019, the RPO “Afif” develops and implements charitable programs and projects in the field of drug prevention, HIV, tuberculosis, sexually transmitted infections (STIs), hepatitis, sexual and reproductive health and other diseases.
The RPO “Afif” mission states:
The efforts of the Republican Public Organization “Afif” (RPO “Afif”) are aimed at the implementation and development of socially useful humanitarian activities by participation in the implementation of national strategies of the Republic of Tajikistan on: improving quality of life, health and social protection of the population; public information and education; ensuring the rights of people affected by HIV, TB, viral hepatitis, convicts, including former convicts, vulnerable women, victims of domestic violence and subjected to social stigma and discrimination, expanding their access to medical, social, psychological and legal services; environmental protection and safety; networking and multisectoral collaboration; advocacy programs aimed on economic stability; capacity building of partner organizations.
This also mentioned is the Strategic Plan of the Organization for the period of 2023-2025 years.
Thus, RPO “Afif” will continue to seek opportunities to develop and realise projects in the field of viral hepatitis prevention in the Republic of Tajikistan.
It implements the project “Assistance in the prevention and control of viral hepatitis in the Republic of Tajikistan”
Objective: Creation of favourable conditions for the prevention of the spread of viral hepatitis among the population through awareness-raising and support for the development of a national program to combat viral hepatitis in the Republic of Tajikistan for 2025-2030.
Tasks:
1. Raising awareness of the general population and vulnerable to viral hepatitis groups on the prevention of viral hepatitis using innovative approaches and reducing the level of discrimination and stigmatization of people associated with viral hepatitis.
2. Assistance in the development of a national program to combat viral hepatitis in the Republic of Tajikistan for 2025-2030, contributing to reducing the spread of viral hepatitis among the population and mortality from these diseases.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close